Thursday 16 October, 2025
Introduction/Objectives The new R package, NMsim [1,2], provides the capability to perform simulations of NONMEM models, including with parameter uncertainty,…
Read morePoster: Methodology - New Modelling Approaches
Joint distribution modelling of drug metabolizing enzymes and transporters expression for PBPK-driven virtual patient simulation
Thursday 16 October, 2025
Introduction In physiologically based pharmacokinetic (PBPK) modelling, the expression levels of drug metabolizing enzymes and transporters (DMET) are essential parameters…
Read morePatient-reported outcomes to inform patient-specific tumor growth inhibition parameters
Thursday 16 October, 2025
Background: Patient-reported outcomes (PROs) are defined by the FDA as “any report of the status of a patient’s health condition…
Read moreContinuous-time Markov models: Investigation into the use of Stan and msm for fitting disease progression models for EDSS in multiple sclerosis
Thursday 16 October, 2025
Introduction: NO.MS is the largest multiple sclerosis (MS) dataset of pooled clinical trials from Novartis, containing data from 35000 patients…
Read moreA trimer-based MABEL approach for the First-In-Human starting dose selection of T-cell Engagers
Thursday 16 October, 2025
Introduction/Objectives: T-cell engagers (TCEs) are promising targeted immunotherapeutic agents, which can redirect the immune system’s T cells to recognize and…
Read moreExtension of IMPRES-M, the smoothing impulse-response PK-PD framework, to population pharmacokinetic analysis
Thursday 16 October, 2025
Introduction Population pharmacokinetic (popPK) modeling is the cornerstone of quantitative pharmacology, but construction of proper PK models can be laborious….
Read moreIntegration of a Novel First-Order Release Z-Factor Dissolution Model with Global Sensitivity Analysis to Guide Formulation Development using Physiologically-Based Biopharmaceutics in OSPSuite v12
Thursday 16 October, 2025
Introduction The Z-factor approach [1] is a widely used dissolution model in developing Physiologically Based Biopharmaceutics Models (PBBM) and represents…
Read morePKPD modeling for rapid dose selection with IMPRES-M, a novel smoothing approach.
Thursday 16 October, 2025
Introduction Selecting optimal doses for repeated administration in clinical trials is a critical task in drug development. Traditional pharmacokinetic (PK)…
Read moreEnhancing Pharmacometric Analyses with Estimand Framework and Causal Inference
Thursday 16 October, 2025
Objective We aim at enhancing the strength of claims that can be made based on pharmacometric analyses by relating them…
Read moreMulti-objective Optimization for Population Pharmacokinetic (PopPK) Model Selection Using NSGA-II and pyDarwin
Thursday 16 October, 2025
Introduction: The selection of a “good” model typically involves both objective (numerical) and subjective criteria. Subjective criteria, such as interpretation…
Read more